Edison, N.J.-based Hackensack Meridian Health is partnering with Neosoma, a medtech company that uses artificial intelligence to research and treat brain tumors.
The health system's clinicians specializing in brain tumors will use Neosoma's technology and provide feedback to the company. Additional parts of the collaboration include data-sharing, clinical research and strategic investment from Hackensack, according to a Feb. 24 Neosoma news release.
Neosoma recently received FDA clearance for its AI-based neuro-health software device, Neosoma HGG.
"Neosoma helps to avoid interruptions in care, unnecessary surgeries, and unnecessary changes in therapy," Joseph Landolfi, DO, a neuro-oncologist and the chief medical officer at the system's Edison, N.J.-based JFK University Medical Center, said in the release. "The entire team benefits from centralized information, more efficient communication, and treatment protocols tailored to each specific patient."